Aptose Biosciences Inc., of San Diego, said it entered an equity distribution agreement with Piper Sandler and Canaccord Genuity that allows the company, from time to time, to issue and sell common shares at-the-market. It will file a prospectus supplement with the SEC qualifying the offer and sale of common shares having an aggregate offering price of up to $75 million.

Algernon Pharmaceuticals Inc., of Vancouver, British Columbia, said it has amended certain terms of its brokered private placement, being conducted by Mackie Research Capital Corp. The company will now issue and sell up to 17.14 million special warrants at CA35 cents each for gross proceeds of up to approximately CA$6 million (US$4.24 million). The net proceeds will be used for ongoing research, clinical trials, working capital and general corporate purposes.

Delcath Systems Inc., of New York, said it closed its underwritten public offering of 2.2 million shares of common stock (or common stock equivalents) and series F warrants to purchase up to 2.2 million shares of common stock for gross proceeds of approximately $22 million.

Kura Oncology Inc., of San Diego, said it priced an underwritten public offering of 9.1 million shares of its common stock at $13.75 each for gross proceeds of approximately $125.1 million. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1.365 million shares of common stock.

Mind Medicine Inc., of Toronto, said it entered an amended letter of engagement with Eight Capital, which has agreed to purchase 21.69 million units of the company on a “bought deal” basis at CA53 cents per unit for gross proceeds of CA$11.5 million (US$8.14 million). The underwriters have been granted an overallotment option to purchase up to an additional 15% of the units. The company intends to use the net proceeds to fund its collaboration with University Hospital Basel’s Liechti Laboratory and for general corporate purposes.

Nascent Biotech Inc., of San Diego, said it has canceled its stock purchase agreement with Triton Funds LLC and discontinued further draw downs on the equity line of credit with Triton.

Oncology Venture A/S, of Horsholm, Denmark, said it has secured a $5 million (SEK50 million) investment and entered a share subscription agreement with Global Corporate Finance (GCF). The funding will support the company’s continuing development and commercialization of its prioritized pipeline of cancer drugs together with their companion diagnostics. The 36-month agreement allows the company to decide to exercise investment by GCF in five tranches of up to $1 million with company shares being issued to GCF.

TG Therapeutics Inc., of New York, said it raised gross proceeds of approximately $60 million through its at-the-market facility, $40 million of which came from longtime shareholder RA Capital Management. The company sold approximately 3.5 million shares at the then-prevailing market prices. It intends to use the capital to fund the ongoing development and commercialization of lead assets, ublituximab and umbralisib, as well as for research and development activities and for general corporate purposes.

Trillium Therapeutics Inc., of Cambridge, Mass., said it has established an at-the-market (ATM) equity program and entered a sales agreement with Evercore Group LLC as agent. Under the program, the company may sell, through the agent, common shares resulting in aggregate gross proceeds of up to $50 million. The volume and timing of distributions under the ATM program, if any, will be determined at the company’s sole discretion. It intends to use the net proceeds for working capital and general corporate purposes.

No Comments